CRIS Current Research Information System

FUSAROLI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.998
NA - Nord America 1.511
EU - Europa 1.364
SA - Sud America 182
AF - Africa 103
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.183
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.465
CN - Cina 944
SG - Singapore 789
IT - Italia 605
VN - Vietnam 508
HK - Hong Kong 248
KR - Corea 167
BR - Brasile 138
IN - India 127
DE - Germania 126
NL - Olanda 109
SE - Svezia 82
GB - Regno Unito 74
FR - Francia 67
JP - Giappone 65
FI - Finlandia 51
RU - Federazione Russa 49
CI - Costa d'Avorio 36
IE - Irlanda 35
ID - Indonesia 32
CA - Canada 30
AT - Austria 28
BG - Bulgaria 24
CH - Svizzera 24
AR - Argentina 23
TG - Togo 21
ES - Italia 20
ZA - Sudafrica 20
AU - Australia 16
TH - Thailandia 15
TR - Turchia 15
BD - Bangladesh 14
IQ - Iraq 14
PL - Polonia 13
GR - Grecia 10
PH - Filippine 10
SA - Arabia Saudita 10
MY - Malesia 9
BE - Belgio 8
NZ - Nuova Zelanda 8
MX - Messico 7
PT - Portogallo 7
UA - Ucraina 7
CO - Colombia 5
JO - Giordania 5
KE - Kenya 5
LT - Lituania 5
NG - Nigeria 5
PK - Pakistan 5
TW - Taiwan 5
EC - Ecuador 4
EG - Egitto 4
JM - Giamaica 4
NP - Nepal 4
PE - Perù 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
CL - Cile 3
GH - Ghana 3
HU - Ungheria 3
MA - Marocco 3
SC - Seychelles 3
VE - Venezuela 3
CZ - Repubblica Ceca 2
HN - Honduras 2
IL - Israele 2
KZ - Kazakistan 2
OM - Oman 2
PY - Paraguay 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
BJ - Benin 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
HR - Croazia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MT - Malta 1
NI - Nicaragua 1
PR - Porto Rico 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 6.183
Salva come PNG Salva come JPEG
Città #
Singapore 554
Hefei 400
Hong Kong 233
Ashburn 227
Bologna 200
Seoul 162
San Jose 153
Ho Chi Minh City 138
Hanoi 129
Santa Clara 93
Chandler 74
Council Bluffs 69
Beijing 63
Los Angeles 56
Boardman 52
Tokyo 50
Milan 44
The Dalles 40
Dallas 39
Lauterbourg 38
Bengaluru 37
Abidjan 36
Dublin 34
Helsinki 34
Princeton 28
Jakarta 26
New York 24
Redmond 24
Sofia 24
Southend 24
Da Nang 23
Haiphong 21
Lomé 21
Redondo Beach 21
Rome 21
Bern 19
Buffalo 19
Frankfurt am Main 19
Modena 19
Shanghai 19
Vienna 18
Orem 16
Biên Hòa 15
Munich 15
Guangzhou 13
Amsterdam 12
Chicago 12
Fairfield 12
Johannesburg 12
Nuremberg 12
São Paulo 12
Tongling 12
Toronto 12
London 11
Atlanta 10
Cesena 10
Florence 10
Turin 10
Bangkok 9
Hangzhou 9
Lappeenranta 9
San Diego 9
Indianapolis 8
Monselice 8
Nha Trang 8
Paris 8
Phoenix 8
Poplar 8
Shenzhen 8
Suzhou 8
Xi'an 8
Can Tho 7
Chengdu 7
Houston 7
Hyderabad 7
New Delhi 7
Ninh Bình 7
Auckland 6
Berlin 6
Brooklyn 6
Brussels 6
Bến Tre 6
Cambridge 6
City of London 6
Denver 6
Embrun 6
Hải Dương 6
Jinan 6
Lizzano 6
Mercato Saraceno 6
Montreal 6
Palermo 6
Perth 6
Pune 6
Seattle 6
Stockholm 6
Turku 6
Verona 6
Visakhapatnam 6
Warsaw 6
Totale 3.819
Salva come PNG Salva come JPEG
Nome #
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 296
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 287
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 219
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 213
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 206
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 201
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 191
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 189
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors 178
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 177
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 174
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 174
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 161
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 160
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase 153
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 148
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 146
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration 138
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System 138
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 132
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 131
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 128
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System 125
Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database 123
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 120
Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list 118
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 118
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study 115
What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System 108
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline 107
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 107
Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system 101
Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System 100
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System 93
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System 93
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal 91
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance 89
Environmental sustainability-an essential component of rational use of medicines 79
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database 74
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system 74
Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance” 73
The evolving role of disproportionality analysis in pharmacovigilance 70
Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports A Note of Caution 68
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System 65
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach 65
Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis 51
Characterizing post-mortem blood concentrations in methadone-related deaths 50
Interpretation of Pharmacovigilance Disproportionality Analyses 40
Real-world evidence and pharmacovigilance: workshop of the Italian Epidemiological Association and of the Italian Society of Pharmacology 34
Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study 26
Transparency and robustness of safety signals 23
Totale 6.340
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.474
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.474
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 8 1 7
2021/2022256 1 0 7 10 10 10 36 47 20 21 58 36
2022/2023478 36 19 31 32 48 38 45 48 81 14 54 32
2023/2024420 36 41 41 56 43 60 22 39 15 30 30 7
2024/20251.651 93 139 165 104 129 66 109 129 65 119 175 358
2025/20263.499 406 508 340 301 330 153 586 184 477 214 0 0
Totale 6.340